Genomics

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

Friday, October 22, 2021 - 11:00am

QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

Key Points: 
  • QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
  • The move into the new facility will help us write the next chapter of this success story.
  • Health Innovation Manchester unites the regions spectrum of public, academic and clinical resources.
  • It is meant to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

Global RNA Analysis Market Research Report 2021 - ResearchAndMarkets.com

Thursday, October 21, 2021 - 3:11pm

The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • RNA species (messenger RNA, transfer RNA, and ribosomal RNA) play an important role in the translation of genetic information from DNA to proteins.
  • This report explores the present and future market values of the RNA analysis market, particularly by type of analysis such as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing.
  • Also included in the report is a discussion of the impact of COVID-19 on the market and profiles of leading companies in the RNA analysis market.

PathAI Welcomes Two New Executives as it Strengthens its Biopharma Business Leadership Team

Thursday, October 21, 2021 - 2:00pm

BOSTON, Oct. 21, 2021 /PRNewswire/ -- PathAI, a leading provider of AI-powered technology, announces that Saumya Pant, Ph.D., joins PathAI as Vice President, Laboratory Strategy and Operations to lead the newly formed PathAI biopharma laboratory business and Jiayi Hao joins as Vice President to lead the overall Biopharma Business Strategy and Operations teams.

Key Points: 
  • BOSTON, Oct. 21, 2021 /PRNewswire/ -- PathAI, a leading provider of AI-powered technology, announces that Saumya Pant, Ph.D., joins PathAI as Vice President, Laboratory Strategy and Operations to lead the newly formed PathAI biopharma laboratory business and Jiayi Hao joins as Vice President to lead the overall Biopharma Business Strategy and Operations teams.
  • "We are pleased to welcome Jiayi and Saumya to the PathAI Biopharma leadership team," said Mike Montalto, PhD, Chief Scientific Officer and President of PathAI's Biopharma Business.
  • Prior to PathAI, Saumya built and led translational and clinical genomics at Bristol Myers Squibb over the last 7 years.
  • Jiayi Hao joins PathAI as VP of Strategy and Operations for PathAI's Biopharma business.

Personalis to Announce Third Quarter Financial Results on November 4, 2021

Thursday, October 21, 2021 - 2:00pm

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021.
  • The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com .
  • Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics.
  • The Personalis Clinical Laboratory is built with a focus on clinical accuracy, quality, big data, scale, and efficiency.

Seven Bridges Unlocks Population-Scale Clinico-Genomic Data for Accelerated Drug Discovery With Commercial Launch of ARIA™

Thursday, October 21, 2021 - 1:00pm

Since the initial announcement of ARIA in February 2020, Seven Bridges has partnered with research institutes and commercial agencies, using ARIA to drive insights from data at the million-participants scale and above.

Key Points: 
  • Since the initial announcement of ARIA in February 2020, Seven Bridges has partnered with research institutes and commercial agencies, using ARIA to drive insights from data at the million-participants scale and above.
  • Today, Seven Bridges is pleased to offer ARIA for biopharmaceutical and clinical researchers to improve and accelerate discovery of outcomes using clinical and genomics data at population scale.
  • Across the world, numerous initiatives are currently underway to collect massive repositories of genomic and phenotypic data.
  • Seven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine.

Digital Supercluster Highlights Top 2021 Digital Innovations That Matter to Canadians

Thursday, October 21, 2021 - 1:00pm

"Three years ago, our model of collaborative innovation did not exist in Canada," said Sue Paish, CEO of Canada's Digital Supercluster.

Key Points: 
  • "Three years ago, our model of collaborative innovation did not exist in Canada," said Sue Paish, CEO of Canada's Digital Supercluster.
  • In addition to these positive impacts on Canadians, the Digital Supercluster is committed to supporting Canadian small and medium enterprises (SMEs).
  • Over 50% of the Digital Supercluster members are SMEs, and over 70% of Supercluster investment in projects goes to SMEs.
  • We accelerate the development and adoption of digital technologies that keep Canadians healthy, address climate change and drive economic productivity.

OpGen Subsidiary Ares Genetics Launches AREScloud

Thursday, October 21, 2021 - 12:30pm

(Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics , which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance (AMR), has commercially launched its AREScloud web application.

Key Points: 
  • (Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics , which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance (AMR), has commercially launched its AREScloud web application.
  • The performance of AREScloud bioinformatics pipelines for isolate WGS has been validated in several clinical studies.
  • OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding the commercial launch of AREScloud, a web application aimed at accelerating the analysis of sequenced clinical isolates.

Orange Grove Bio, AlleyCorp and Alexandria Venture Investments Establish Partnership with Albert Einstein College of Medicine to Support Development of Novel Therapeutics

Thursday, October 21, 2021 - 11:00am

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth of innovative healthcare and life science companies, today announced the formation of a partnership program with Albert Einstein College of Medicine to support the development of novel therapeutics. Through the newly established program, Einstein scientists will have the opportunity to receive expert mentorship and financial support to advance their foundational research and streamline translation of their discoveries into new drug candidates.

Key Points: 
  • NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth of innovative healthcare and life science companies, today announced the formation of a partnership program with Albert Einstein College of Medicine to support the development of novel therapeutics.
  • Program participants will be selected by an expert panel of scientists, investors and drug development professionals based on submitted applications.
  • Selected project teams will receive more than six months of director mentorship designed to assist in translating their discoveries into novel therapeutic candidates.
  • Through this new partnership, Orange Grove Bio, AlleyCorp and Alexandria Venture Investments are working to leverage our combined expertise in drug development, company formation and fundraising to support Einstein scientists in translating their groundbreaking discoveries into the impactful treatments of tomorrow.

DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director

Thursday, October 21, 2021 - 10:00am

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.

Key Points: 
  • DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.
  • The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets.
  • Moukheibir brings over 30 years of leadership experience in finance, capital markets and life sciences to DNA Script.
  • DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform, said Thomas Ybert, DNA Script co-founder and CEO.

Twist Bioscience Launches Exome 2.0 for Genomics Research

Wednesday, October 20, 2021 - 1:00pm

Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • With the launch of Exome 2.0, we now offer a complete portfolio of flexible, comprehensive exome options to support genomics researchers looking to identify the underpinnings of disease.
  • The Twist Exome 2.0 is an exome panel designed with thoughtfully curated content that includes comprehensive coverage of genes responsible for rare diseases, inherited disorders, and germline cancers in humans.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.